Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening

References

• Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613–619.
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–4775.
   PubMed Web of Science ®Google Scholar
• Fontana E, Gaillard R. [Epidemiology of pituitary adenoma: results of the first Swiss study]. Rev Med Suisse. 2009;5:2172–2174.
   PubMedGoogle Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377–382.
   PubMed Web of Science ®Google Scholar
• Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010;95:4268–4275.
   PubMed Web of Science ®Google Scholar
• Cannavo S, Ferrau F, Ragonese M, et al. Increased prevalence of acromegaly in a highly polluted area. Eur J Endocrinol. 2010;163:509–513.
   PubMed Web of Science ®Google Scholar
• Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545–553.
   PubMed Web of Science ®Google Scholar
• Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015;173:655–664.
   PubMed Web of Science ®Google Scholar
• Al-Dahmani K, Mohammad S, Imran F, et al. Sellar masses: an epidemiological study. Can J Neurol Sci. 2016;43:291–297.
   PubMed Web of Science ®Google Scholar
• McDowell BD, Wallace RB, Carnahan RM, et al. Demographic differences in incidence for pituitary adenoma. Pituitary. 2011;14:23–30.
   PubMed Web of Science ®Google Scholar
• Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother. 2008;8:563–574.
   PubMedGoogle Scholar
• Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228–1230.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ramirez LC, Gabrovska P, Denes J, et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab. 2015;100:E1242–54.
   PubMed Web of Science ®Google Scholar
• Leontiou CA, Gueorguiev M, Van Der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93:2390–2401.
   PubMed Web of Science ®Google Scholar
• Igreja S, Chahal HS, King P, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31:950–960.
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373–83.
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92:1891–1896.
   PubMed Web of Science ®Google Scholar
• Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371:2363–2374.
   PubMed Web of Science ®Google Scholar
• Gordon RJ, Bell J, Chung WK, et al. Childhood acromegaly due to X-linked acrogigantism: long term follow-up. Pituitary. 2016;19:560–564.
   PubMed Web of Science ®Google Scholar
• Daly AF, Yuan B, Fina F, et al. Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocr Relat Cancer. 2016;23:221–233.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Caswell R, Bunce B, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016;4:56.
   PubMed Web of Science ®Google Scholar
• Beckers A, Lodish MB, Trivellin G, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015;22:353–367.
   PubMed Web of Science ®Google Scholar
• Beckers A, Fernandes D, Fina F, et al. Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism. Endocr Relat Cancer. 2017;24:L17–L20.
   PubMedGoogle Scholar
• Lecoq AL, Bouligand J, Hage M, et al. Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas. Eur J Endocrinol. 2016;174:523–530.
   PubMed Web of Science ®Google Scholar
• Ferrau F, Romeo PD, Puglisi S, et al. Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine. 2016;54:762–767.
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Izawa M, Fukuoka H, et al. Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma. Endocr J. 2016;63:953–963.
   PubMed Web of Science ®Google Scholar
• Trivellin G, Correa RR, Batsis M, et al. Screening for GPR101 defects in pediatric pituitary corticotropinomas. Endocr Relat Cancer. 2016. doi: 10.1530/ERC-16-0091
   Web of Science ®Google Scholar
• De Laat JM, Dekkers OM, Pieterman CR, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100:3288–3296.
   PubMed Web of Science ®Google Scholar
• Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–465.
   PubMed Web of Science ®Google Scholar
• Cuny T, Pertuit M, Sahnoun-Fathallah M, et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur J Endocrinol. 2013;168:533–541.
   PubMed Web of Science ®Google Scholar
• Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100:1177–1186.
   PubMed Web of Science ®Google Scholar
• Boyce AM, Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington. 2015.
   Google Scholar
• Salenave S, Boyce AM, Collins MT, et al. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab. 2014;99:1955–1969.
   PubMed Web of Science ®Google Scholar
• De Kock L, Sabbaghian N, Plourde F, et al. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 2014;128:111–122.
   PubMed Web of Science ®Google Scholar
• Sahakitrungruang T, Srichomthong C, Pornkunwilai S, et al. Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing’s disease. J Clin Endocrinol Metab. 2014;99:E1487–92.
   PubMed Web of Science ®Google Scholar
• Trivellin G, Korbonits M. AIP and its interacting partners. J Endocrinol. 2011;210:137–155.
   PubMed Web of Science ®Google Scholar
• Heliovaara E, Raitila A, Launonen V, et al. The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am J Pathol. 2009;175:2501–2507.
   PubMed Web of Science ®Google Scholar
• Chahal HS, Trivellin G, Leontiou CA, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012;97:E1411–20.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Prezant TR, Une KN, et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab. 1999;84:249–256.
   PubMed Web of Science ®Google Scholar
• Billestrup N, Swanson LW, Vale W. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci U S A. 1986;83:6854–6857.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228–252.
   PubMed Web of Science ®Google Scholar
• Formosa R, Xuereb-Anastasi A, Vassallo J. Aip regulates cAMP signalling and GH secretion in GH3 cells. Endocr Relat Cancer. 2013;20:495–505.
   PubMed Web of Science ®Google Scholar
• Tuominen I, Heliovaara E, Raitila A, et al. AIP inactivation leads to pituitary tumorigenesis through defective Galphai-cAMP signaling. Oncogene. 2015;34:1174–1184.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Wildemberg LE, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012;19:L25–9.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174:241–250.
   PubMed Web of Science ®Google Scholar
• Jaffrain-Rea ML, Rotondi S, Turchi A, et al. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer. 2013;20:753–766.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Tichomirowa MA, Sievers C, et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer. 2009;125:2122–2126.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006;66:1576–1582.
   PubMed Web of Science ®Google Scholar
• Naves LA, Daly AF, Vanbellinghen JF, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol. 2007;157:383–391.
   PubMed Web of Science ®Google Scholar
• Chahal HS, Stals K, Unterlander M, et al. AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med. 2011;364:43–50.
   PubMed Web of Science ®Google Scholar
• Williams F, Hunter S, Bradley L, et al. Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. J Clin Endocrinol Metab. 2014;99:1122–1131.
   PubMed Web of Science ®Google Scholar
• Xekouki P, Mastroyiannis SA, Avgeropoulos D, et al. Familial pituitary apoplexy as the only presentation of a novel AIP mutation. Endocr Relat Cancer. 2013;20:L11–4.
   PubMed Web of Science ®Google Scholar
• Oriola J, Lucas T, Halperin I, et al. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol. 2013;168:9–13.
   PubMed Web of Science ®Google Scholar
• Stiles CE, Korbonits M. Familial Isolated Pituitary Adenoma. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. 2000.
   Google Scholar
• Villa C, Lagonigro MS, Magri F, et al. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr Relat Cancer. 2011;18:347–356.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Bouligand J, Salenave S, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012;97:E663–70.
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Heliovaara E, Paschke R, et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J Clin Endocrinol Metab. 2008;93:4146–4151.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Guillaud-Bataille M, Bertherat J, et al. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res. 2009;71:132–141.
   PubMedGoogle Scholar
• Hernandez-Ramirez LC, Martucci F, Morgan RM, et al. Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J Clin Endocrinol Metab. 2016;101:3144–3154.
   PubMed Web of Science ®Google Scholar
• Rostomyan L, Daly AF, Petrossians P, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22:745–757.
   PubMed Web of Science ®Google Scholar
• Yu R, Bonert V, Saporta I, et al. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab. 2006;91:5126–5129.
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A. 2007;104:4101–4105.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Libe R, Perlemoine K, et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol. 2007;157:1–8.
   PubMed Web of Science ®Google Scholar
• Barlier A, Vanbellinghen JF, Daly AF, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab. 2007;92:1952–1955.
   PubMed Web of Science ®Google Scholar
• DiGiovanni R, Serra S, Ezzat S, et al. AIP Mutations are not identified in patients with sporadic pituitary adenomas. Endocr Pathol. 2007;18:76–78.
   PubMed Web of Science ®Google Scholar
• Iwata T, Yamada S, Mizusawa N, et al. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf). 2007;66:499–502.
   PubMed Web of Science ®Google Scholar
• Georgitsi M, De Menis E, Cannavo S, et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf). 2008;69:621–627.
   PubMed Web of Science ®Google Scholar
• Occhi G, Trivellin G, Ceccato F, et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol. 2010;163:369–376.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78:457–463.
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165:509–515.
   PubMed Web of Science ®Google Scholar
• Cai F, Zhang YD, Zhao X, et al. Screening for AIP gene mutations in a Han Chinese pituitary adenoma cohort followed by LOH analysis. Eur J Endocrinol. 2013;169:867–884.
   PubMed Web of Science ®Google Scholar
• Schofl C, Honegger J, Droste M, et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. J Clin Endocrinol Metab. 2014;99:E2789–93.
   PubMed Web of Science ®Google Scholar
• Preda V, Korbonits M, Cudlip S, et al. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Eur J Endocrinol. 2014;171:659–666.
   PubMed Web of Science ®Google Scholar
• Karaca Z, Taheri S, Tanriverdi F, et al. Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant? Pituitary. 2015;18:831–837.
   PubMed Web of Science ®Google Scholar
• Ramirez-Renteria C, Hernandez-Ramirez LC, Portocarrero-Ortiz L, et al. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. Endocrine. 2016;53:402–411.
   PubMed Web of Science ®Google Scholar
• Ritvonen E, Pitkanen E, Karppinen A, et al. Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol. 2017;176:243–252.
   PubMed Web of Science ®Google Scholar
• Rodd C, Millette M, Iacovazzo D, et al. Somatic GPR101 duplication causing X-linked acrogigantism (XLAG)-Diagnosis and management. J Clin Endocrinol Metab. 2016;101:1927–1930.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Korbonits M. Gigantism:X-linked acrogigantism and GPR101 mutations. Growth Horm IGF Res. 2016;30-31:64–69.
   PubMed Web of Science ®Google Scholar
• Naves LA, Daly AF, Dias LA, et al. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine. 2015;51:236–244.
   PubMed Web of Science ®Google Scholar
• Daly AF, Lysy P, Defilles C, et al. Growth hormone releasing hormone excess and blockade in X-LAG syndrome. Endocr Relat Cancer. 2015;23:161–170.
   PubMed Web of Science ®Google Scholar
• Ferrau F, Romeo PD, Puglisi S, et al. Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine; 2016. doi: 10.1007/s12020-016-0862-4
   Google Scholar
• Korbonits M, Dutta P, Reddy KS, et al. Exome sequencing reveals double hit by AIP gene mutation and copy loss of chromosome 11 but negative X-LAG in a pituitary adenoma of a 4 year old child with gigantism treated with multimodal therapy. Endocrine Society’s 98th Annual Meeting and Expo; 2016.
   Google Scholar
• Bates B, Zhang L, Nawoschik S, et al. Characterization of Gpr101 expression and G-protein coupling selectivity. Brain Res. 2006;1087:1–14.
   PubMed Web of Science ®Google Scholar
• Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. 2006;1:38.
   PubMedGoogle Scholar
• Dreijerink KM, Goudet P, Burgess JR, et al. International Breast Cancer in MENSG. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014;371:583–584.
   PubMed Web of Science ®Google Scholar
• Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–407.
   PubMed Web of Science ®Google Scholar
• Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29:22–32.
   PubMed Web of Science ®Google Scholar
• Concolino P, Costella A, Capoluongo E. Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years. Cancer Genet. 2016;209:36–41.
   PubMed Web of Science ®Google Scholar
• Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998;62:232–244.
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Lee JE, Shapiro SE, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002;137:641–647.
   PubMedGoogle Scholar
• Horiuchi K, Okamoto T, Iihara M, et al. Analysis of genotype-phenotype correlations and survival outcomes in patients with primary hyperparathyroidism caused by multiple endocrine neoplasia type 1: the experience at a single institution. Surg Today. 2013;43:894–899.
   PubMed Web of Science ®Google Scholar
• Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386:2–15.
   PubMed Web of Science ®Google Scholar
• Milne TA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A. 2005;102:749–754.
   PubMed Web of Science ®Google Scholar
• Kaji H, Canaff L, Lebrun JJ, et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A. 2001;98:3837–3842.
   PubMed Web of Science ®Google Scholar
• Ikeo Y, Yumita W, Sakurai A, et al. JunD-menin interaction regulates c-Jun-mediated AP-1 transactivation. Endocr J. 2004;51:333–342.
   PubMed Web of Science ®Google Scholar
• Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332:85–87.
   PubMed Web of Science ®Google Scholar
• Dong Q, Debelenko LV, Chandrasekharappa SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1997;82:1416–1420.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Labat-Moleur F, Sturm N, et al. Groupe d’etudes des Tumeurs E. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32:534–543.
   PubMed Web of Science ®Google Scholar
• Borson-Chazot F, Garby L, Raverot G, et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Ann Endocrinol (Paris). 2012;73:497–502.
   PubMed Web of Science ®Google Scholar
• Prezant TR, Levine J, Melmed S. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab. 1998;83:1388–1391.
   PubMed Web of Science ®Google Scholar
• Farrell WE, Simpson DJ, Bicknell J, et al. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. Br J Cancer. 1999;80:44–50.
   PubMed Web of Science ®Google Scholar
• Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990–3011.
   PubMed Web of Science ®Google Scholar
• Tonelli F, Giudici F, Giusti F, et al. A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. Eur J Endocrinol. 2014;171:K7–K17.
   PubMed Web of Science ®Google Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103:15558–15563.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94:1826–1834.
   PubMed Web of Science ®Google Scholar
• Malanga D, De Gisi S, Riccardi M, et al. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol. 2012;166:551–560.
   PubMed Web of Science ®Google Scholar
• Occhi G, Regazzo D, Trivellin G, et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. Plos Genet. 2013;9:e1003350.
   PubMed Web of Science ®Google Scholar
• Sambugaro S, Di Ruvo M, Ambrosio MR, et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5ʹUTR region. Endocrine. 2015;49:58–64.
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92:3321–3325.
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Lee M, Barlier A, et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer. 2012;19:233–241.
   PubMed Web of Science ®Google Scholar
• Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol. 2015;173:M85–97.
   PubMed Web of Science ®Google Scholar
• Stratakis CA. Carney complex: a familial lentiginosis predisposing to a variety of tumors. Rev Endocr Metab Disord. 2016;17:367–371.
   PubMed Web of Science ®Google Scholar
• Salpea P, Horvath A, London E, et al. Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab. 2014;99:E183–8.
   PubMed Web of Science ®Google Scholar
• PRKAR1A Mutation Database [ cited 2009]. Available from: https://prkar1a.nichd.nih.gov/hmdb/intro.html.
   Google Scholar
• Horvath A, Bossis I, Giatzakis C, et al. Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res. 2008;14:388–395.
   PubMed Web of Science ®Google Scholar
• Forlino A, Vetro A, Garavelli L, et al. PRKACB and Carney complex. N Engl J Med. 2014;370:1065–1067.
   PubMed Web of Science ®Google Scholar
• Watson JC, Stratakis CA, Bryant-Greenwood PK, et al. Neurosurgical implications of Carney complex. J Neurosurg. 2000;92:413–418.
   PubMed Web of Science ®Google Scholar
• Pack SD, Kirschner LS, Pak E, et al. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). J Clin Endocrinol Metab. 2000;85:3860–3865.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86:4041–4046.
   PubMed Web of Science ®Google Scholar
• Bertherat J, Horvath A, Groussin L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5ʹ-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab. 2009;94:2085–2091.
   PubMed Web of Science ®Google Scholar
• Lonser RR, Mehta GU, Kindzelski BA, et al. Surgical management of Carney complex-associated pituitary pathology. Neurosurgery. 2016. doi: 10.1227/NEU.0000000000001384
   Google Scholar
• Stergiopoulos SG, Abu-Asab MS, Tsokos M, et al. Pituitary pathology in Carney complex patients. Pituitary. 2004;7:73–82.
   PubMedGoogle Scholar
• Armstrong DK, Irvine AD, Handley JM, et al. Carney complex: report of a kindred with predominantly cutaneous manifestations. Br J Dermatol. 1997;136:578–582.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Salpea P, Raygada M. Carney Complex. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington. 2015.
   Google Scholar
• Kaltsas GA, Kola B, Borboli N, et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf). 2002;57:443–448.
   PubMed Web of Science ®Google Scholar
• Benn DE, Robinson BG, Clifton-Bligh RJ. 15 YEARS OF PARAGANGLIOMA: clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer. 2015;22:T91–103.
   PubMed Web of Science ®Google Scholar
• Denes J, Swords F, Rattenberry E, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab. 2015;100:E531–41.
   PubMed Web of Science ®Google Scholar
• Xekouki P, Szarek E, Bullova P, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab. 2015;100:E710–9.
   PubMed Web of Science ®Google Scholar
• Dwight T, Mann K, Benn DE, et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab. 2013;98:E1103–8.
   PubMed Web of Science ®Google Scholar
• Xekouki P, Pacak K, Almeida M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J Clin Endocrinol Metab. 2012;97:E357–66.
   PubMed Web of Science ®Google Scholar
• O’Toole SM, Denes J, Robledo M, et al. 15 YEARS OF PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer. 2015;22:T105–22.
   PubMed Web of Science ®Google Scholar